Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome

Human Reproduction Update

Volumn 14, Issue 4, 2008, Pages 321-333

  Soares, Sérgio Reis ^a   Gómez, Rául ^b   Simón, Carlos ^b   García Velasco, Juan Antonio ^c   Pellicer, Antonio ^b,d  

^a INSTITUTO VALENCIANO DE INFERTILIDAD   (Portugal)

^b UNIVERSITY OF VALENCIA   (Spain)

^c INSTITUTO VALENCIANO DE INFERTILIDAD   (Spain)

^d HOSPITAL UNIVERSITARIO DR PESET   (Spain)

Author keywords

Dopamine agonist; Ovarian hyperstimulation syndrome; Pathophysiology; Vascular endothelial growth factor; Vascular permeability

Indexed keywords

CABERGOLINE; CELL ADHESION MOLECULE; CHORIONIC GONADOTROPIN; DOCARPAMINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; GONADORELIN DERIVATIVE; LUTEINIZING HORMONE DERIVATIVE; MESSENGER RNA; PERGOLIDE; PLACEBO; RECOMBINANT LUTEINIZING HORMONE; SEMAXANIB; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ARTICLE; BLOOD VESSEL PERMEABILITY; CELL JUNCTION; CLINICAL TRIAL; CORPUS LUTEUM; CORRELATION ANALYSIS; DISEASE SEVERITY; DNA FLANKING REGION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GRANULOSA CELL; HEART VALVE REGURGITATION; HUMAN; HYPERPROLACTINEMIA; IMMUNOHISTOCHEMISTRY; INCIDENCE; INFORMATION RETRIEVAL; LOW DRUG DOSE; LUTEAL CELL; MEDLINE; NONHUMAN; OOCYTE DONATION; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; THROMBOEMBOLISM; VOMITING;

ANIMALS; CAPILLARY PERMEABILITY; CELLS, CULTURED; CHORIONIC GONADOTROPIN; CLINICAL TRIALS AS TOPIC; DOPAMINE AGONISTS; ERGOLINES; ESTRADIOL; ESTROGENS; FEMALE; HUMANS; INDOLES; MICROFILAMENTS; OVARIAN HYPERSTIMULATION SYNDROME; PHOSPHORYLATION; PYRROLES; RATS; REPRODUCTIVE CONTROL AGENTS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 45549084382     PISSN: 13554786     EISSN: 14602369     Source Type: Journal    
DOI: 10.1093/humupd/dmn008     Document Type: Article

References (139)

1. Aboulghar MA, Mansour RT. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum Reprod Update 2003; 9:275-289.
2. Aboulghar MA, Mansour RT, Serour GI, El-Helw BA, Shaarawy M. Elevated concentrations of angiogenin in serum and ascitic fluid from patients with severe ovarian hyperstimulation syndrome. Hum Reprod 1998; 13: 2068-2071.
3. Aboulghar MA, Mansour RT, Serour GI, El Helw BA, Shaarawy M. Elevated levels of interleukin-2, soluble interleukin receptor alpha, interleukin-6, soluble interleukin receptor and vascular endothelial growth factor in serum and ascitic fluid in patients with severe ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol 1999; 87:81-85.
4. Abramov Y, Barak V, Nisman B, Schenker JG. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertil Steril 1997; 67:261-265.
5. Agrawal R, Tan SL, Wild S, Sladkevicius P, Engmann L, Payne N, Bekir J, Campbell S, Conway G, Jacobs H. Serum vascular endothelial growth factor concentrations in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome. Fertil Steril 1999; 71:287-293.
6. Albert C, Garrido N, Mercader A, Rao CV, Remohi J, Simon C, Pellicer A. The role of endothelial cells in the pathogenesis of ovarian hyperstimulation syndrome. Mol Hum Reprod 2002; 8:409-418.
7. Álvarez C, Martí-Bonmatí L, Novella-Maestre E, Sanz R, Goómez R, Fernández-Sánchez M, Simon C, Pellicer A. Dopamine agonist cabergoline reduces haemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 2007a: 92:2931-2937.
8. Álvarez C, Alonso-Muriel I, García G, Crespo J, Bellver J, Simón C, Pellicer A. Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome (OHSS) in women undergoing ART. A pilot study. Hum Reprod 2007b; 22:3210-3214.
9. Amarin ZO. Bilateral partial oophorectomy in the management of severe ovarian hyperstimulation syndrome. An aggressive, but perhaps life-saving procedure. Hum Reprod 2003; 18:659-664.
10. Antczak M, Van Blerkom J. The vascular character of ovarian follicular granulosa cells: Phenotypic and functional evidence for an endothelial-like cell population. Hum Reprod 2000; 15 2306-2318.
11. Artini PG, Fasciani A, Monti M, Luisis S, D́Ambrogio G, Genazzani AR. Changes in vascular endothelial growth factor concentrations and the risk of ovarian hyperstimalation syndrome in women enrolled in an in vitro fertilization program. Fertil Steril 1998; 70:560-564.
12. Asch RH, Balmaceda JP, Weckstein LN, Stone SC. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups. Hum Reprod 1991; 6:1395-1399.
13. Balasch J, Arroyo V, Fábregues F, Jiménez W, Saló J, Vanrell JA. Immnoreactive endothelin plasma levels in severe ovarian hyperstimulation syndrome. Fertil Steril 1995; 64:65-68.
14. Balasch J, Fabregues F, Arroyo V. Peripheral arterial vasodilation hypothesis: A new insight into the pathogenesis of ovarian hyperstimulation syndrome. Hum Reprod 1998; 13:2718-2730.
15. Barak V, Elchalal U, Edelstein M, Kalickman I, Lewin A, Abramov Y. Interleukin-18 levels correlate with severe ovarian hyperstimulation syndrome. Fertil Steril 2004; 82:415-420.
16. Basu S, Dasgupta PS. Alteration of dopamine D2 receptors in human malignant stomach tissue. Dig Dis Sci 1997; 42:1260-1264.
17. Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, Manseau EJ, Dasgupta PS, Dvorak HF, Mukhopadhyay D. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 2001; 7:569-574.
18. Basu S, Sarkar C, Chakroborty D, Nagy J, Mitra RB, Dasgupta PS, Mukhopadhyay D. Ablation of peripheral dopaminergic nerves stimulates, malignant tumor growth by inducing vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis. Cancer Res 2004; 64:5551-5555.
19. Bates DO, Harper SJ. Regulation of vascular permeability by vascular endothelial growth factors. Vascul Pharmacol 2002; 39 225-237.
20. Bates DO, Lodwick D, William B. Vascular endothelial growth factor and microvascular permeability. Microcirculation 1999; 6:83-96.
21. Bates DO, Hillman NJ, Williams B, Neal CR, Pocock TM. Regulation of microvascular permeability by vascular endothelial growth factors. J Anat 2002; 200:581-597.
22. Bhattacharjee G, Asplin IR, Wu SM, Gawdi G, Pizzo SV. The conformation-dependent interaction of a2-macroglobulin with vascular endothelial growth factor. J Biol Chem 2000; 275:26806-26811.
23. Bigazzi M, Ronga R, Lancranjan I, Ferraro S, Branconi F, Buzzoni P, Martorana G, Scarselli GF, Del Pozo E. A pregnancy in an acromegalic woman during bromocriptine treatment: Effects on growth hormone and prolactin in the maternal, fetal, and amniotic compartments. J Clin Endocrinol Metab 1979; 48:9-12.
24. Blumenfeld Z, Lang N, Amit A, Kahana L, Yoffe N. Native gonadotropin-releasing hormone for triggering follicular maturation in polycystic ovary syndrome patients undergoing human menopausal gonadotropin ovulation induction. Fertil Steril 1994; 62 456-460.
25. Blumenfeld Z, Shabadash V, Shen-Or Z, Arnon R, Israeli E, Makler A. The origin of ascites in the ovarian hyperstimulation syndrome is mainly ovarian in humans. In: Program and Abstracts of the Annual Meeting of the Society for Gynecological Investigation, San Diego, CA. J Soc Gynecol Invest 1997;(Suppl 4). Abstract 123.
26. Bohnet HG, Muhlenstedt D, Hanker JP, Schneider HP. Prolactin oversuppression. Arch Gynakol 1977; 223:173-178.
27. Borna S, Nasery A. Spontaneous ovarian hyperstimulation in a pregnant woman with hypothyroidism. Fertil Steril 2007; 88 705.el-705.e3.
28. Cappa F, Pasqua C, Tobia M, Ventura T. Ascites and hydrothorax due to endogenous hyperstimulation of H.C.G. in a case of hydatidiform mole destruens with secondary irreversible kidney insufficiency due to disseminated intravascular coagulation. Rivista Italiana di Ginecologia 1976; 56:363-368.
29. Chen CD, Wu MY, Chen HF, Chen SU, Ho HN, Yang YS. Prognostic importance of serial cytokine changes in ascites and pleural effusion in women with severe ovarian hyperstimulation syndrome. Fertil Steril 1999; 72:286-292.
30. Chen CD, Chen HF, Lu HF, Chen SU, Ho HN, Yang YS. Value of serum and follicular fluid cytokine profile in the prediction of moderate to severe ovarian hyperstimulation syndrome. Hum Reprod 2000; 15 1037-1042.
31. Ciccarelli E, Grottoli S, Razzore P, Gaia D, Bertagna. A, Cirillo S, Cammarota T, Camanni M, Camanni F. Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy. J Endocrinol Invest 1997; 20:547-551.
32. De Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular enclothelial growth factor. Science 1992; 255:989-991.
33. Delbaere A, Smits G, De Leener A, Costagliola S, Vassart G. Understanding ovarian hyperstimulation syndrome. Endocrine 2005; 26:285-290.
34. Delvigne A, Rozenberg S. Systematic review of data concerning ethiopathology of ovarian hyperstimulation syndrome. Int J Fertil Womens Med 2002; 47:211-226.
35. Delvigne A, Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome. Hum Reprod Update 2003; 9 77-96.
36. Diedrich K, Ludwig M, Felberbaum RE. The role of gonadotrophin-releasing hormone antagonists in in vitro fertilization. Sem Reprod Med 2001; 19:213-220.
37. Doldi N, Bassan M, Fusi F, Ferrari A. In controlled ovarian hyperstimulation, steroid production, oocyte retrieval, and pregnancy rate correlate with gene expression of vascular endothelial growth factor. J Assist Reprod Genet 1997; 14:589-592.
38. Eljarmak D, Lis,M, Cantin M, Carriere PD, Collu R. Effects of chronic bromocriptine treatment of an estrone-induced, prolactin-secreting rat pituitary adenoma. Horm Res 1985; 21:160-167.
39. Ferraretti AP, Gianaroli L, Diotallevi L, Festi C, Trounson AO. Dopamine treatment for severe ovarian hyperstimulation syndrome. Hum Reprod 1992; 7:180-183.
40. Friedlander MA, Loret de Mola JR, Goldfarb JM. Elevated levels of interleukin-6 in ascites and serum from women with ovariana hyperstimulation syndrome. Fertil Steril 1993; 60:826-833.
41. Gaddy-Kurten D, Hickey GJ, Fey GH, Gauldie J, Richards JS. Hormonal regulation and tissue-specific localization of alpha2-macroglobulin in rat ovarian follicles and corpora lutea. Endocrinology 1999; 125:2995-2995.
42. Galway AB, LaPolt PS, Tsafriri A, Dargan CM, Boine I, Hsueh AJ. Recombinant follicle-stimulating hormone induces ovulation and tissue plasminogen activator expression in hypophysectomized rats. Endocrinology 1990; 127:3023-3028.
43. Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, Pelletier N, Ferrara N. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 2001; 276:3222-3230.
44. Glade-Bender J, Kandel JJ, Yamashiro DJ. VEGF blocking therapy in the treatment of cancer. Expert Opin Biol Ther 2003; 3:263-276.
45. Golan A, Ron-El R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: An update review. Obstet Gynecol Surv 1989; 44:430-440.
46. Gómez R, Simon C, Remohi J, Pellicer A. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology 2002; 143:4339-4348.
47. Gómez R, Simón C, Remohí J, Pellicer A. Administration of moderate and high doses of gonadotrophins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability. Biol Reprod 2003a; 68:2164-2171.
48. Gómez R, González M, Simón C, Remohi J, Pellicer A. Tyroxine hydroxylase (TH) downregulation in hyperstimulated ovaries reveals the dopamine agonist bromocriptine (Br2) as an effective and specific method to block increased vascular permeability (VP) in OHSS. Fertil Steril 2003b; 80(Suppl 3):43-44.
49. Gómez R, Lima I, Simón C, Pellicer A. Administration of low-dose LH induces ovulation and prevents vascular hyperpermeability and vascular endothetial growth factor expression in superovulated rats. Reproduction 2004; 127:483-489.
50. Gómez R, González-Izquierdo M, Zimmermann RC, Novella-Maestre E, Alonso-Muriel I, Sanchez-Criado J, Remohí J, Simón C, Pellicer A. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpemeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 2006; 147:5400-5411.
51. Guo D, Jia Q, Song HY, Warren SR, Donner DB. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediator of signal transduction that contains SH2 domains. Association with endothelial cell proliferation. J Biol Chem 1995; 270:6729-6733.
52. Gutman G, Soussan-Gutman L, Malcov M, Lessing JB, Amit A, Azem F. Interleukin-18 is high in the serum of IVF pregnancies with ovarian hyperstimulation syndrome. Am J Reprod Immunol 2004; 51: 381-384.
53. Guvenal F, Guvenal T, Tinturoglu Y, Timuroglu T, Cetin M. Spontaneous ovarian hyperstimulation-like reaction caused by primary hypothyroidism. Acta Obstet Gynecol Scand 2006; 85:124-125.
54. Haning RV, Jr, Austin CW, Carlson IH, Kusam DL, Shapiro SS, Zweibel WL. Plasma estradiol is superior to ultrasound and urinary estriol glucorinide as a predictor of ovarian hyperstimulation during induction of ovulation with menotropins. Fertil Steril 1983; 40:31-36.
55. Heryanto B, Lipson KE, Rogers PA. Effect of angiogenesis inhibitors on oestrogen-mediated endometrial endothelial cell proliferation in the ovariectomized mouse. Reproduction 2003; 125:337-346.
56. Horning C, Behn T, Bartsch W, Yayon A, Weich HA. Detection and quantification of complexed and free soluble human vascular endothelial growth factor receptor- 1 (sVEGFR- 1) by ELISA. J Immunol Methods 1999; 226:169-177.
57. Kamat BR, Brown LF, Mauseau EJ, Senger DR, Dvorak HF. Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca. lutein cells. Role in corpus luteum development. Am J Pathol 1995; 146:157-165.
58. Katz J, Lancet M, Borenstein R, Chemke J. Absence of teratogenicity of indomethacin in ovarian hyperstimulation syndrome. Int J Fertil 1984; 29:186-188.
59. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246:1309-1312.
60. Kendall RL, Thomas KA. Inhibition of vascular endothelial growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993; 90:10705-10709.
61. Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, flt-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 1996; 226:324-328.
62. Kihara M, Sugita T, Nagai Y, Saeki N, Tatsuno I, Seki K. Ovarian hyperstimulation caused by gonadotroph cell adenoma: A case report and review of the literature. Gynecol Endocrinol 2006; 22 110-113.
63. Knoepfelmacher M, Danilovic DL, Rosa Nasser RH, Mendonca BB. Effectiveness of treating ovarian hyperstimulation syndrome with cabergoline in two patients with gonadotrophin-producing pituitary adenomas. Fertil Steril 2006; 86:e15-e18.
64. Kobayashi H, Okada Y, Asahina T, Gotoh J, Terao T. The kallikrein-kinin system, but not vascular endothelial growth factor, plays a role in the increased vascular permeability associated with ovarian hyperstimutation syndrome. J Mol Endocrinol 1998; 20:363-374.
65. Koos RD, Olson CE. Hypoxia stimulates expression of the gene for vascular endothelial growth factor (VEGF), a putative angiogenic factor, by granulosa cells of the ovarian follicle, a site of angiogenesis. J Cell Biol 1991; 115:421a.
66. Kuenen BC, Tabernero J, Baselga J, Cavalli F, Pfanner E, Conte PF, Seeber S, Madhusudan S, Deplanque G, Huisman H et al. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin Cancer Res 2003; 9:1648-1655.
67. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitrogen. Science 1989; 246:1306-1309.
68. Liu C, Tyrrell JB. Successful treatment of a large macroprolactinoma with cabergoline during pregnancy. Pituitary 2001; 4:179-185.
69. Ludwig M, Jelkmann W, Bauer O, Diedrich K. Prediction of severe ovarian hyperstimulation syndrome by free serum vascular endothelial growth factor concentration on the day of human chorionic gonadotrophin administration. Hum Reprod 1999; 14:2437-2441.
70. Manau D, Balasch J, Arroyo V, Jimenez W, Fabregues F, Casamitjana R, Creus M, Vanrell JA. Circulatory dysfunction in asymptornatic in vitro fertilization patients. Relationship with hyperstrogenemia and activity of endogenous vasodilators. J Cliiu Endocrinol Metab 1998; 83 1489-1493.
71. Manau D, Arroyo V, Jimenez W, Fabregues F, Vanrell JA, Balasch J. Hemodynamic changes in asymptomatic in vitro fertilization patients: chronological characterization over the luteal phase and relationship with ovarian steroids and cytokines. Fertil Steril 2002a; 77 1178-1183.
72. Manau D, Fabregues F, Arroyo V, Jimenez W, Vanrell JA, Balasch J. Hemodynamic changes induced by urinary human chorionic gonadotrophin and recombinant luteinizing hormone used for inducing final follicular maturation and luteinization. Fertil Steril 2002b; 78 1261-1267.
73. Manno M, Tomei F, Marchesan E, Adamo V. Cabqrgoline: A safe, easy, cheap, and effective drug for prevention/treatment of ovarian hyperstimulation syndrome? Eur J Obstet Gynecol Reprod Biol 2005; 122:127-128.
74. Manolopoulos K, Lang U, Gips H, Braems GA. Elevated interleukin- 10 and sex steroid levels in peritoneal fluid of patients with ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol 2001; 99:226-231.
75. McClure N, Healy DL, Rogers PA, Sullivan J, Beaton L, Haning RV, Jr, Connolly DT, Robertson DM. Vascular endothelial cell growth factor as permeability agent in ovarian hyperstimulation syndrome. Lancet 1994; 344:235-236.
76. McElhinney B, Ardill J, Caldwell C, Lloyd F, McClure N. Ovarian hyperstimulation syndrome and assisted reproductive technologies: Why some and not others? Hum Reprod 2002; 17:1548-1553.
77. Molskness TA, Stouffer RL, Burry KA, Gorrill MJ, Lee DM, Patton PE. Circulating levels of free and total vascular endothelial growth factor (VEGF)-A, soluble VEGF receptors-1 and -2, and angiogenin during ovarian stimulation in non-human primates and women. Hum Reprod 2004; 19:822-830.
78. Montanelli L, Delbaere A, Di Carlo C, Nappi C, Smits G, Vassart G, Costagliola S. A mutation in the follicle-stimulating hormone receptor as a cause of familial spontaneous ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 2004a; 89:1255-1258.
79. Montanelli L, Van Durme JJ, Smits G, Bonomi M, Rodien P, Devor EJ, Moffat-Wilson K, Pardo L, Vassart G, Costagliola S. Modulation of ligand selectivity associated with activation of the transmembrane region of the human follitropin receptor. Mol Endocrinol 2000; 18 2061-2073
80. Montgomery-Rice VC, Zusmanis K, Malter H, Mitchell-Leef D. Pure FSH alone induces ovulation and subsequent pregnancy in the mouse resulting in fetal development. Life-Sci 1993; 53:31-39.
81. Mornex R, Orgiazzi J, Hugues B, Gagnaire JC, Claustrat B. Normal pregnancies after treatment of hyperprolactinemia with bromoergocryptine, despite suspected pituitary tumors. J Clin Endocrinol Metab 1978; 47:290-295.
82. Mozes M, Bogowsky H, Anteby E, Lunenfeld B, Rabau E, Serr DM, David A, Salomi M. Thrombo-embolic phenomena after ovarian stimulation with human menopausal gonadotrophins. Lancet 1965; 2:1213-1215.
83. Mueller GP, Simpkins J, Meites J, Moore KE. Differential effects of dopamine agonists and haloperidol on release of prolactin, thyroid stimulating hormone, growth hormone and luteinizing hormone in rats. Neuroendocrinology 1976; 20:121-135.
84. Navot D, Margalioth El, Laufer N, Birkenfeld A, Relou A, Rosler A, Schenker JG. Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome. Fertil Steril 1987; 48:57-61.
85. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: Prevention and treatment. Fertil Steril 1992; 58:249-261.
86. Navot D, Bergh PA, Laufer N. The ovarian hyperstimulation syndrome. In: Adashi EY, Rock JA, Rosenwaks Z (ed). Reproductive Endocrinology, Surgery and Technology. Philadelphia: Lippincott-Raven Pub, 1996, 2225-2232.
87. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13 9-22.
88. Neulen J, Yan Z, Raczek S, Weindel K, Keck C, Weich HA, Marine D, Breckwoldt M. Human chorionic gonadotrophin-dependent expression of vascular endothelial growth factor/VP factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 1995; 80: 1967-1971.
89. Neulen J. Werizel D. Hornig C, Wunsch E, Weissenborn U, Grunwald K, Buttner R, Weich H. Poor responder-high responder: The importance of soluble vascular endothelial growth factor. Hum Reprod 2001; 16 621-626.
90. Olson TA, Mohanraj D, Carson LF, Ramakrishnan S. VP factor gene expression in normal and neoplastic human ovaries. Cancer Res 1994; 54:276-280.
91. Orvieto R, Voliovitch I, Fishman P, Ben-Rafael Z. Interleukin-2 and ovarian hyperstimulation syndrome: A pilot study. Hum Reprod 1995; 10:24--27.
92. Özden S, G⊣ulrbüz B, Yalti S, Ergül B, Özturkmen M. Ovarian hyperstimulation associated with a spontaneous pregnancy. J Obstet Gynaecol 2005; 25:394-395.
93. Papaleo E, Doldi N, De Santis L, Marelli G, Marsiglio E, Rofena S, Ferrari A. Cabergoline influences ovarian stimulation in hyperprolactinaernic patients with polycystic ovary syndrome. Hum Reprod 2001; 16:2263-2266.
94. Parast CV, Mroczkowski B, Pinko C, Misialek S, Khambatta. G, Appelt K. Characterization and kinetic mechanism of catalytic domain of human vascular endothelial growth factor receptor-2 tyrosine kinase (VEGFR-2TK), a key enzyme in angiogenesis. Biochemistry 1998; 37:16788-16801.
95. Pau E, Alonso-Muriel I, Gómez R, Novella-Maestre E, Ruiz A, Garía-Velasco J-A, Simón C, Pellicer A. Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome. Hum Reprod 2006; 21:1453-1460.
96. Pauli SA, Tang- H, Wang J, Bohlen P, Posser R, Hartman T, Sauer MV, Kitajewski J, Zimmermann RC. The vascular endothelial growth factor (VEGF)/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent. Endocrinology 2005; 146:1301-1311.
97. Pellicer A, Parmer TG, Stoane JM, Behrman HR. Desensibilization to follicle-stimulating hormone in cumulus cells, is coincident with hormone induction of oocyte maturation in rat follicle. Mol Cell Endocrinol 1989; 64:179-188.
98. Pellicer A, Miró F, Sampaio, M, Gómez E, Bonilla-Musoles FM. In vitro fertilization as a diagnostic and therapeutic tool in a patient with partial 17,20-desmolase deficiency. Fertil Steril 1991; 55 970-975.
99. Pellicer A, Albert C, Mercader A, Bonilla-Musoles F, Remohi J, Simon C. The pathogenesis of ovarian hyperstimulation syndrome: In vivo studies investigating the role of interleukin-lbeta, interleukin-6, and vascular endothelial growth factor. Fertil Steril 1999; 71:482-489.
100. Phillips HS, Hains J, Leung DW, Ferrara N. Vascular endothelial growth factor is expressed in rat corpus luteum. Endocrinology 1990; 127:965-967.
101. Quinn TP, Peters KG, De Vries C, Ferrara N, Williams LT. Fetal liver kinase is a receptor for VEGF and is selectively expressed in vascular endothelium. Proc Natl Acad Sci USA 1993; 90:7533-7537.
102. Revel A, Barak V, Lavy Y, Anteby E, Abramov Y, Schenker JJ, Amit A, Finci-Yeheskel Z, Mayer M, Simon A et al. Characterization of intraperitoneal cytokines and nitrites in women with severe ovarian hyperstimulation syndrome. Fertil Steril 1996; 66:66-71.
103. Ricci E, Parazzini F, Motta T, Ferrari Cl, Colao, A, Clavennia A, Rocchi F, Gangi E, Paracchi S, Gasperi M et al. Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 2002; 16:791-793.
104. Rizk B. Ovarian Hyperstimulation Syndrome - Epidemiology, Pathophysiology, Prevention and Management, 1st edn. New York: Cambridge University Press, 2006, 10-33.
105. Rizk B, Smitz J. Ovarian hyperstimulation syndrome after superovulation for IVF and related procedures. Hum Reprod 1992; 7:320-327.
106. Rizk B, Aboulghar M, Smitz J, Ron-El R. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Hum Reprod Update 1997; 3:255-266.
107. Robert E, Musatti L, Piscitelli G, Ferrari CI. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 1996; 10:333-337.
108. Rockwell LC, Pillai S, Olson CE, Koos RD. Inhibition of vascular endothelial growth factor/vascular permeability factor action blocks estrogen-induced uterine edema and implantation in rodents. Biol Reprod 2002; 67:1804-1810.
109. Roeckle W, Hecht D, Sztajer H, Waltenberger J, Yayon A, Weich RA. Differential binding characteristics and cellular inhibition by soluble VEGF receptor 1 and 2. Exp Cell Res 1998; 241:161-170.
110. Sarkar C, Chakroborty D, Mitra RB, Banerjee S, Dasgupta PS, Basu S. Dopamine in vivo inhibits VEGF-induced phosphorylation of VEGFR-2, MAPK, and focal adhesion kinase in endothelial cells. Am J Physiol Heart Circ Physiol 2004; 287:H1554-H1560.
111. Schade R, Andershon S, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Eng J Med 2007; 356:29-38.
112. Schenker JG. Prevention and treatment of ovarian hyperstimulation. Hum Reprod 1993; 8:653-659.
113. Schenker JG. Clinical aspects of ovarian hyperstimulation syndrome. Eur J Gynecol Reprod Biol 1999; 85:13-20.
114. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Shuh AC. Failure of blood island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995; 376:62-66.
115. Shelesnyak MC. Disturbance of hormone balance in the female rat by a single injection of ergoloxinie ethanesulphonate. Am J Physiol 1955; 180:47-49.
116. Simon A, Revel A, Hurwitz A, Laufer N. The pathogenesis of ovarian hyperstimulation syndrome: A continuing enigma. J Assist Reprod Genet 1998; 15:202-209.
117. Smits G, Olatunbosun O, Delbaere A, Pierson R, Vassart G, Costagliola S. Ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor. N Engl J Med 2003; 21 760-766.
118. Soker S, Svahn CM, Neufeld G. Vascular endothelial growth factor is inactivated by binding to alpha2-macroglobulin and the binding is inhibited by heparin. J Biol Chem 1993;268:7685-7691.
119. The European Recombinant LH Study Group. Recombinant human luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotrophin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: Results of a multicenter double-blind study. J Clin Endocrinol Metab 2001; 86:2607-2618.
120. Tsunoda T, Shibahara H, Hirano Y, Suzuki T, Fujiwara H, Takarnizawa S, Ogawa S, Motoyama M, Suzuki M. Treatment for ovarian hyperstimulation syndrome using an oral doparnine prodrug, docarpamine. Gynecol Endocrinol 2003; 17:281-286.
121. Ujioka T, Matsuura K, Kawano T. Okamura H. Role of progesterone in capillary permeability in hyperstimulated rats. Hum Reprod 1997; 12: 1629-1634.
122. Ujioka T, Matsuura K, Tanaka N, Okamura H. Involvement of ovarian kinin-kallikrein system in the pathophysiology of ovarian hyperstimulation syndrome: Studies in a rat model. Hum Reprod 1998; 13: 3009-3015.
123. Vanrell JA, Balasch J. Prolactin in the evaluation of luteal phase in infertility. Fertil Steril 1983; 39:30-33.
124. Vasseur C, Rodien P, Beau I, Desroches A, Gerard C, de Poncheville L, Chaplot S, Savagner F, Croue A, Mathieu E et al. A chorionic gonadotrophin-sensitive mutation in the follicle-stimulating hormone receptor as a cause of familial gestational spontaneous ovarian hyperstimulation syndrome. N Engl J Med 2003; 21:753-759.
125. Villasante A, Pacheco A, Zúñiga A, Pellicer A, Garcia-Velasco JA. Ovarian hyperstimulation syndrome: The role of vascular endothelial cadherin. Hum Reprod 2003; 18:35 (abstract).
126. Villasante A, Pacheco A, Ruiz A, Pellicer A, Garcia-Velasco JA. Vascular endothelial cadherin regulates vascular permeability: Implications for ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 2007; 92:314-321.
127. Vlahos NF, Gregoniou O. Prevention and management of ovarian hyperstimulation syndrome. Ann N YAcad Sci 2006; 1092 247-264.
128. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. Different signal transduction properties of KDR and Fit 1, two receptors for vascular endothelial growth factor. J Biol Chem 1994; 269 26988-26995.
129. Wang TH, Horng SG, Chang CL, Wu HM, Tsai YJ, Wang HS, Soong YK. Human chorionic gonadotrophin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothetial growth factor. J Clin Endocrinol Metab 2002; 87:3300-3308.
130. Wulff C, Wilson H, Rudge JS, Wiegand SJ, Lunn SF, Fraser RM. Luteal angiogenesis: Prevention and intervention by treatment with vascular endothelial growth factor trap (A40). J Clin Endocrinol Metab 2001; 86:3377-3386.
131. Yamamoto S, Konishi I, Tsuruta Y, Nanbu K, Mandai M, Kuroda H, Matsushita K, Hamid AA, Yura Y, Mori T. Expression of vascular endothelial growth factor (VEGF) during folliculogenesis and corpus luteum formation in the human ovary. Gynecol Endocrinol 1997; 11:371-381.
132. Yan Z, Weich HA, Bernart W, Breckwoldt M, Neulen J. Vascular endothelial growth factor (VEGF) messenger ribonucleic acid (mRNA) expression in luteinized human granulosa cells in vitro. J Clin Endocrinol Metab 1993; 77:1723-1725.
133. Yen SSC, Itlenera G, Little B, Pearson O. Disappearance rate of endogenous luteinizing hormone and chorionic gonadotrophin in man. J Clin Endocrinol Metab 1968; 28:1763-1767.
134. Zalel Y, Orvieto R, Ben-Rafael Z, Homburg R, Fisher O, Insler V. Recurrent spontaneous ovarian hyperstimulation syndrome associated with polycystic ovary syndrome. Gynecol Endocrinol, 1995; 9: 313-315.
135. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Eng J Med 2007; 356:39-46.
136. Zelinski-Wooten MB, Hutchison JS, Hess DL, Wolf DP, Stouffer RL. A bolus of recombinant human follicle stimulating hormone at midcycle induces periovulatory events following multiple follicular development in macaques. Hum Reprod 1998;13:554-560.
137. Zimmermann RC, Hartman T, Bohlen P, Sauer MV, Kitajewski J. Preovulatory treatment of mice with anti-VEGF receptor 2 antibody inhibits angiogenesis in corpora lutea. Microvasc Res 2001a;62:15-25.
138. Zimmermann RC, Xiao E, Husami N, Sauer MV, Lobo R, Kitajewski J, Ferin M. Short-term administration of antivascular endothelial growth factor antibody in the late follicular phase delays follicular development in the rhesus monkey. J Clin Endocrinol Metab 2001b;86:768-772.
139. Zimmermann RC, Hartman T, Kavic S, Pauli SA, Bohlen P, Sauer MV, Kitajewski J. Vascular endothelial growth factor receptor 2-mediated angiogenesis is essential for gonadotrophin-dependent follicle development. J Clin Invest 2003;112:659-669.